Andrew Kin, MD

Articles by Andrew Kin, MD

Craig Cole, MD, an expert on multiple myeloma, presenting slides

Cross Q&A: Role of Belantamab Mafodotin in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 17th 2023

The panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.

DREAMM-3: Belantamab Mafodotin in Patients With Relapsed/Refractory MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 10th 2023

Craig Cole, MD, reviews data from DREAMM-3 on the efficacy and safety of single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Faiz Anwer, MD, an expert on multiple myeloma, presenting slides

Cross Q&A: Clinical Application of Ixa-Len-Dex for Patients With MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 10th 2023

Experts on multiple myeloma discuss the clinical applications of ixazomib-lenalidomide-dexamethasone combination therapy.

John Molina, MD, MEd, an expert on chronic myeloid leukemia

OPTIC Trial: 3-Year Data Update in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

John C. Molina, MD, EdM, reviews data from the 3-year update from the OPTIC study, and other experts offer their impressions.

Charles A. Schiffer, MD, an expert on chronic myeloid leukemia

Clinical Applications for Asciminib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Experts in the field of chronic myeloid leukemia discuss the role of asciminib in the overall treatment landscape.

REMIX: Real-World Effectiveness of Ixazomib with Lenalidomide and Dexamethasone in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Faiz Answer, MD, FACP, reviews data from the REMIX study on the real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma.

Jeffrey A. Zonder, MD, an expert on multiple myeloma

Cross Q&A: Retrospective Study of Patients With MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

November 3rd 2023

Experts in the field of multiple myeloma discuss data from a retrospective study on patients with multiple myeloma.

ASCEMBL: Recent Data Updates for Asciminib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

Charles A. Schiffer, MD, reviews clinical trial data for asciminib in chronic myeloid leukemia and highlights financial toxicity concerns.

Moaath Mustafa Ali, MD, MPH, an expert on chronic myeloid leukemia

Potential Role of Olverembatinib in CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

The expert panel discusses the potential role of olverembatinib in the chronic myeloid leukemia treatment landscape.

Outcomes After Biochemical or Clinical Progression in Patients with MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

Jeffrey A. Zonder, MD, reviews data on patient outcomes following biochemical or clinical progression in multiple myeloma.

Jack Khouri, MD, an expert on multiple myeloma

Cross Q&A: Efficacy of CAR T-Cell Therapy in MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 27th 2023

The expert panel discusses the efficacy and durability of response of ciltacabtagene autoleucel in patients with multiple myeloma.

Olverembatinib in Patients with Pretreated/Refractory CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Moaath Mustafa Ali, MD, MPH, reviews data on olverembatinib in patients with heavily pretreated/refractory chronic myeloid leukemia.

Jay Yang, MD, an expert on chronic myeloid leukemia, presenting clinical trial data

Treatment Considerations for Ponatinib in Patients With CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Expert perspectives on treatment considerations for ponatinib in patients with chronic myeloid leukemia.

CARTITUDE-4: Cilta-Cel in Lenalidomide-Refractory MM

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Jack Khouri, MD, discusses phase 3 results from the CARTITUDE-4 study investigating ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma.

Andrew Kin, MD, an expert on multiple myeloma

Cross Q&A: Treatment Considerations for Ixa-Pom-Dex in Multiple Myeloma

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 20th 2023

Following a review of data from the ALLIANCE A061202 study, experts on multiple myeloma discuss treatment considerations for patients being treated with ixazomib, pomalidomide, and dexamethasone.

Ponatinib Dose-Ranging Data in Chronic-Phase CML

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

Jay Yang, MD, reviews data from the OPTIC trial, a ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia.

The host of Cancer Network's Face-Off program shown with an introductory slide

Team Introductions: CML Experts From Karmanos Cancer Institute and Cleveland Clinic

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

A panel of experts on chronic myeloid leukemia from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in the disease space.

ALLIANCE A061202: Ixazomib Plus Pomalidomide and Dexamethasone in Multiple Myeloma

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

Andrew Kin, MD, reviews data on the addition of ixazomib to pomalidomide and dexamethasone in patients with multiple myeloma who progressed on lenalidomide in the first line.

Team Introductions: MM Experts From Karmanos Cancer Institute and Cleveland Clinic

ByAndrew Kin, MD,Jeffrey Zonder, MD,Craig Cole, MD,Jay Yang, MD,Charles A. Schiffer, MD,Jack Khouri, MD,Faiz Anwer, MD,John Molina, MD, MEd,Moaath Mustafa Ali, MD, MPH

October 13th 2023

A panel of experts on multiple myeloma from Karmanos Cancer Institute and Cleveland Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent data in multiple myeloma.